NanoVibronix, Inc. (NASDAQ:NAOV) has reported positive outcomes from a study of its UroShield device conducted at the University of Southampton. The study found that UroShield had a positive effect on catheter-associated urinary tract infections (CAUTI) and catheter blockage, with about one-third of patients citing a reduction in the frequency of catheter blockages. The device generates ultrasonic waves to prevent bacterial biofilm formation and may reduce the need for antibiotics.